Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference Sep 23, 2019 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019 Aug 08, 2019 Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma Aug 01, 2019 Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets Jul 30, 2019 First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology Jun 13, 2019 Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019) Jun 11, 2019 Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting Jun 01, 2019 Nektar Announces the Launch of Inheris Biopharma, Inc. May 23, 2019 Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting May 15, 2019 Nektar Therapeutics Reports Financial Results for the First Quarter of 2019 May 08, 2019 Pagination First page « first Previous page ‹ previous … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page next › Last page last »